ArticlePharmacoEconomics2022

Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.

Tingting Qu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.